SCHEMBL29951655

SCHEMBL29951655

O=Cc1c[nH]c2c(F)c(Cl)ccc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
PIM3 Q86V86 10/20 0.46
PIM1 P11309 8/20 0.46
PIM2 Q9P1W9 2/20 0.46
CYP2A6 P11509 2/20 0.41
IMPDH2 P12268 1/20 0.41
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
PLG P00747 1/20 0.36
PLAU P00749 1/20 0.36
GPR17 Q13304 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534041 1.00 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29951142 0.82 TRIM24 (0.50) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL2539628 0.82 TRIM24 (0.50) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL17829692 0.82 CSNK2A2 (0.50) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29957633 0.79 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL30859480 0.79 PIM3 (0.51) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29958526 0.79 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL31656115 0.79 TRIM24 (0.56) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29956475 0.79 PIM3 (0.55) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL17828249 0.79 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-10 US disclosed
EP-4582420-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF MDM2, TP53, TP53BP1 TRIM24 581/4885TRIM33 972/4885PIM3 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.